BAUSCH + LOMB IRELAND LIMITED

The present disclosure provides polymorphs and formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present disclosure further provides methods for treating ocular surface pain by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.

A monofunctional urea-based organosilicon monomer represented by a structure of Formula I: wherein R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , m and n are as defined herein. An ophthalmic device having optical clarity is a polymerization product of a monomeric mixture including (a) one or more monofunctional urea-based organosilicon monomers represented by a structure of Formula I, and (b) one or more ophthalmic device-forming hydrophilic comonomers or polymers.

An ophthalmic device which is a polymerization product of a monomeric mixture including (a) one or more monofunctional urea-based silicone monomers represented by a structure of Formula I: wherein each R 1 is independently an alkyl group; R 2 is an alkyl group or a trialkyl siloxy group, R 3 is an alkylene group, R 4 is hydrogen or methyl and n is an integer from 1 to 12, (b) one or more ophthalmic device-forming hydrophilic comonomers or polymers, and (c) one or more cross-linking agents. The ophthalmic device is optically clear.

The present disclosure provides polymorphs and formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present disclosure further provides methods for treating ocular surface pain by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.

A grafted glycosaminoglycan polymer is disclosed. The grafted glycosaminoglycan polymer comprises a glycosaminoglycan having a polymer backbone and one or more side chains comprising a polyalkylene glycol-containing residue grafted onto the polymer backbone.

A surface modified ophthalmic device includes a silicone ophthalmic device having a hydrophilic surface coating attached to a surface of the silicone ophthalmic device by van der Waals dispersion forces, the hydrophilic surface coating comprising a copolymer comprising (i) monomeric units derived from an ethylenically unsaturated-containing monomer having ring-opening reactive functionalities, and (ii) monomeric units derived from a hydrophilic monomer having an ethylenically unsaturated reactive group.

A multifunctional crosslinking agent includes one or more repeating units of a siloxanyl group or a silyl-alkyl-siloxanyl group, and at least two ethylenically unsaturated reactive end groups. One of the at least two ethylenically unsaturated reactive end groups is a (meth)acrylate-containing reactive end group or an acrylamide-containing reactive end group and the other one is an allyl-containing reactive end group or a vinyl-containing reactive end group. Ophthalmic devices are formed from a polymerization product of a monomeric mixture containing one or more of the multifunctional crosslinking agents, one or more first ophthalmic device-forming comonomers having at least one reactive group that preferentially reacts with the (meth)acrylate-containing reactive end group or the acrylamide-containing reactive end group of the multifunctional crosslinking agent, and one or more second ophthalmic device-forming comonomers having at least one reactive group that preferentially reacts with the allyl-containing reactive end group or the vinyl-containing reactive end group of the multifunctional crosslinking agent.

A method for preparing an ophthalmic device for slowing, inhibiting or preventing myopia progression involves contacting an ophthalmic device having one or more reactive functional groups with one or more red-light blocking compounds having one or more reactive functional groups complementary to the one or more reactive functional groups of the ophthalmic device in a basic solution for a time period sufficient to covalently bond at least one reactive functional group of the ophthalmic device with at least one reactive functional group of the one or more red-light blocking compounds. The one or more red-light blocking compounds block greater than about 5% to about 25% of red-light transmission through the ophthalmic device at a wavelength of from about 550 nanometers (nm) to about 800 nm.

A packaging system for the storage of an ophthalmic device is disclosed. The packaging system includes a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution that includes one or more conjugated glycosaminoglycans having a polymer backbone having a reactive functional moiety conjugated to an amine group having one or more moieties that inhibit and/or prevent one or more of oxidation and hydrolytic degradation of the polymer backbone during use in the eye; wherein the aqueous packaging solution has an osmolality of at least about 150 mOsm/kg, a pH of about 6 to about 9 and is sterilized.

Multi-dose preservative-free ocular fluid delivery devices are provided. The fluid delivery device includes a fluid dispensing system and a fluid package for storing a liquid therein and supplying said liquid to the dispensing system. The dispensing system comprises an elongated chamber which includes a check valve which defines a frontal closure to the chamber. The valve is normally closed and hermetically seals the chamber. The dispenser includes a vibration motor that induces oscillations to the chamber and to the fluid within. The oscillations of the chamber impart momentum to the fluid stored in the chamber which in turn imparts force that cyclically opens the valve to dispense streams or liquid droplets. Fluid is dispensed only when the motor oscillates while otherwise the valve is hermetically closed. The fluid package can be made collapsible to remove the need to vent it.